lɪˈɑːɾə hɐz ˈɔːlsoʊ kˈoʊɪnvˈɛntᵻd ˈʌðɚ klˈɪnɪkəl ˈeɪdʒənts fɔːɹ tɹˈiːɾɪŋ ˌeɪtʃˌaɪvˈiː ˈɛlvjuːsˌɪɾɐbˌaɪn, kˈɜːɹəntli ɪn fˈeɪz tˈuː klˈɪnɪkəl tɹˈaɪəlz ænd hˈɑːt flˈæʃᵻz ɪn pˈoʊstmˈɛnəpˌɔːzəl wˈɪmɪn ænd wˈɪmɪn wɪð bɹˈɛst kˈænsɚ kjˈuː wˈʌnhˈʌndɹɪd twˈɛnti tˈuː, kˈɜːɹəntli ɪn fˈeɪz tˈuː klˈɪnɪkəl tɹˈaɪəlz æz wˈɛl æz ɐ sˌiːdˌiːkˈeɪ sˈɛvən ɪnhˈɪbɪɾɚ fɔːɹ tɹˈiːɾɪŋ vˈɛɹiəs kˈænsɚz sˌiːtˈiː sˈɛvən θˈaʊzənd wˈʌn, səksˈɛsfəli kəmplˈiːɾᵻd ɐ fˈeɪz wˈʌn klˈɪnɪkəl tɹˈaɪəl.
Liotta has also co-invented other clinical agents for treating HIV (elvucitabine, currently in Phase 2 clinical trials) and hot flashes in post-menopausal women and women with breast cancer (Q-122, currently in Phase 2 clinical trials) as well as a CDK7 inhibitor for treating various cancers (CT7001, successfully completed a Phase 1 clinical trial).